Compare NC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | ACIU |
|---|---|---|
| Founded | 1913 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.7M | 247.6M |
| IPO Year | 2006 | 2015 |
| Metric | NC | ACIU |
|---|---|---|
| Price | $38.66 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 15.1K | ★ 180.6K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $104,778,000.00 | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $38.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.69 | $2.10 |
| 52 Week High | $59.42 | $4.00 |
| Indicator | NC | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 49.62 |
| Support Level | N/A | $2.57 |
| Resistance Level | $44.04 | $2.68 |
| Average True Range (ATR) | 1.25 | 0.13 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 1.25 | 19.05 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.